| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9351984 | PLX PHARMA | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Dec, 2021
(2 years ago) | |
| US8865187 | PLX PHARMA | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(2 years ago) | |
| US9101637 | PLX PHARMA | Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(2 years ago) | |
| US9226892 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US9216150 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US10786444 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US10646431 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
Vazalore is owned by Plx Pharma.
Vazalore contains Aspirin.
Vazalore has a total of 7 drug patents out of which 3 drug patents have expired.
Expired drug patents of Vazalore are:
- US9351984
- US8865187
- US9101637
Vazalore was authorised for market use on 26 February, 2021.
Vazalore is available in capsule;oral dosage forms.
Vazalore can be used as a method of targeting release of a non-steroidal anti-inflammatory drug (nsaid) to the small intestine of the subject when administered orally, temporary reduction of fever, temporary relief of minor aches and pains.
The generics of Vazalore are possible to be released after 29 September, 2032.
Drugs and Companies using ASPIRIN ingredient
Market Authorisation Date: 26 February, 2021
Treatment: Temporary relief of minor aches and pains; Temporary reduction of fever; A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid) to the small intestine of the subject when admi...
Dosage: CAPSULE;ORAL
VAZALORE family patents
